InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (6 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
6
T+90 hit rate
42%
T+90 mean return
-0.2%
Across 19 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by HIGGINS JOHN L, Chairman & CEO. Officer active across 3 companies, notably Ligand Pharmaceuticals INC. In total, 45 filings have been recorded. Split: 3 buys · 6 sells. Total volume traded: €2.8m. Activity tracked since 30 June 2021. The latest transaction was filed on 12 May 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations45 total
65,000 shares@ US$1.4412.8% of flowCommon StockSEC:0001628280-25-025224:0
Ideal exit: 6 Feb 2026 (T+270)
12,000 shares@ US$21.8419.9% of flowCommon StockSEC:0001062993-25-008474:0
4,000 shares@ US$2.281.3% of flowCommon StockSEC:0001846253-25-000030:0
Ideal exit: 16 Dec 2025 (T+270)
125,750 shares@ US$2.3541.2% of flowCommon StockSEC:0001846253-25-000028:0
Ideal exit: 15 Dec 2025 (T+270)
13,172 sharesCommon StockSEC:0001846253-25-000008:0
1,462 shares0Common StockSEC:0001062993-24-018031:0
6,000 shares@ US$22.9510.6% of flowCommon StockSEC:0001062993-24-016642:0
6,000 shares@ US$22.9510.9% of flowCommon StockSEC:0001062993-24-013645:0
20,000 sharesCommon StockSEC:0001846253-24-000054:0
4,000 shares@ US$22.957.3% of flowCommon StockSEC:0001062993-24-010446:0
2,427,861 sharesCommon StockSEC:0001846253-24-000016:0
13,173 sharesCommon StockSEC:0002001011-24-000011:0
1,625 shares0Common StockSEC:0001062993-23-019850:0
25,914 shares@ US$3.6613.6% of flowCommon StockSEC:0001846253-23-000087:0
9,000 shares@ US$3.684.7% of flowCommon StockSEC:0001846253-23-000078:0
1,000 shares@ US$3.680.5% of flowCommon StockSEC:0001846253-23-000076:0
50,000 shares@ US$3.6826.0% of flowCommon StockSEC:0001846253-23-000074:0
16,000 shares@ US$21.8527.1% of flowCommon StockSEC:0001062993-23-009932:0
39,517 shares0Common StockSEC:0001846253-23-000011:0
5,289 shares@ US$66.298.0% of flowCommon StockSEC:0000899243-22-039580:0
10,000 shares@ US$61.865714.1% of flowCommon StockSEC:0000899243-22-039130:0
20,000 shares@ US$12.785.9% of flowCommon StockSEC:0000899243-22-038478:0
9,803 shares@ US$72.9016.7% of flowCommon StockSEC:0000899243-22-037329:0
10,000 shares@ US$78.317318.2% of flowCommon StockSEC:0000899243-22-036575:0
45,922 shares0Common StockSEC:0000899243-22-035035:0
25 of 45 declarations
About HIGGINS JOHN L
John L. Higgins is the Chief Executive Officer and Director of Ligand Pharmaceuticals Inc and Bio-Techne Corp. In these roles, he is responsible for the strategic direction of the companies and the management of their operations. Higgins plays a key role in developing growth initiatives and implementing the companies' vision. His leadership and expertise in the biopharmaceutical sector strengthen Ligand and Bio-Techne's market position.
